Latest market price
9.53
-0.55-5.46%
OverviewShort InterestFilings
NVAXQT72Novavax, Inc.·NASDAQ
9.53-5.46%
Earnings
Down 5.5% — Earnings due 2026-11-05 — pre-report positioning.
Medium confidence
TA
Loading chart...
Signal & projected range
Short-squeeze setupHistorical pattern — not a prediction
Recent priceDays this stock last showed the setupRange of past outcomes (±1σ)
Horizon
0%Past 3 monthsToday
Unlock the projected rangeSee where this setup landed historically — with Premium.
Unlock with Premium

Over the next 20 trading days, similar setups historically landed in a measured range of outcomes. Unlock with Premium to see the median return, the typical range, and how often they were positive. This is the historical range of outcomes — not a prediction of this stock’s price.

Ranges describe how this exact setup resolved in the past — derived from thousands of historical occurrences across QuoTrend’s coverage since 2006, survivorship-corrected to include companies that later delisted. The band is the typical spread (±1σ) of those outcomes, not a forecast; the central value is their average move. Fewer matching cases over longer horizons widen the band and lower its reliability. Backtested results are hypothetical, based on historical data, and do not represent actual trading. Past performance does not guarantee or predict future results. QuoTrend is an educational research tool, not investment advice. Markets involve risk, including loss of principal.

Screen all →
QURE-7.49%$22.97RARE+1.24%$16.30NUVB-3.57%$4.59TRAX-0.07%$45.05NTLA-6.50%$11.66ABSI-12.94%$9.69URGN+5.01%$34.36MAZE-3.53%$30.37
Snapshot
Index—P/E—EPS (ttm)-0.60Insider Own1.49%Shs Outstand164.95MPerf Week1.38%
Market Cap1.57BForward P/E—EPS next Y-0.03Insider Trans0.00%Shs Float146.21MPerf Month-8.89%
Enterprise Value1.14BPEG—EPS next Q-0.35Short Float32.38%Perf Quarter24.41%
Income440.00MP/S1.40EPS this Y-126.55%Short Ratio8.16Perf Half Y18.68%
Sales1.12BP/B—EPS next Y—ROA-25.92%Short Interest47.35MPerf YTD41.82%
Book/sh-1.16P/C2.19EPS next 5Y—ROE—52W High13.39 -28.83%Perf Year13.05%
Cash/sh4.36P/FCF—EPS past 3/5Y—ROIC-36.14%52W Low6.20 53.71%Perf 3Y48.44%
Dividend Est.—EV/EBITDA2.33Sales past 3/5Y-11.11% 119.58%Gross Margin77.85%Volatility7.66% 9.72%Perf 5Y-92.96%
Dividend TTM—EV/Sales1.02EPS Y/Y TTM-167.26%Oper. Margin-54.94%ATR (14)0.87Perf 10Y-68.65%
Dividend Ex-Date—Quick Ratio2.30Sales Y/Y TTM-61.63%Profit Margin-59.87%RSI (14)41.02Recom2.48
Dividend Gr. 3/5Y—Current Ratio2.33EPS Q/Q-151.61%SMA20-13.86%Beta2.77Target Price18.00
Payout0.00%Debt/Eq—Sales Q/Q-76.15%SMA50-8.99%Rel Volume0.64Prev Close10.08
Employees749LT Debt/Eq—EarningsNov 05SMA2002.44%Avg Volume6.40MPrice9.53
IPO DateDec 05, 1995Option/ShortYes / YesEPS/Sales Surpr.15.75% —Net Debt/EBITDA-0.87Volume4,077,126Change-5.46%
Analyst Ratings
DateActionAnalystRatingTarget
Oct-24-25InitiatedCantor FitzgeraldOverweight$18
Oct-23-25ReiteratedHC Wainwright & Co.Buy$19 → $11
Aug-20-25DowngradeB of A SecuritiesNeutral → Underperform
Nov-18-24ReiteratedB.Riley FinancialBuy$22
Oct-16-24ReiteratedJefferiesBuy$31 → $25
Oct-16-24ReiteratedBank of America Securities$14
Jul-30-24DowngradeJP MorganNeutral → Underweight
Jul-19-24ReiteratedJefferiesBuy$38 → $31
May-10-24UpgradeB of A SecuritiesUnderperform → Neutral
Aug-09-23UpgradeB. Riley SecuritiesNeutral → Buy
Latest News· Times ET
Oct-29-26
Oct-29-2611:06AM
Novavax (NVAX) May Report Negative Earnings: Know the Trend Ahead of Q3 Releasezacks.com
09:37AM
Novavax Earns $125 Million Milestone as Sanofi Launches Phase 3 Influenza-COVID-19 Combination Vaccine Trial in Europeprnewswire.com
08:00AM
Novavax to Report Third Quarter 2026 Financial Results on November 5, 2026prnewswire.com
Oct-28-26
Oct-28-2612:04PM
Moderna Jumps 4% Despite William Blair Downgrade on Valuation; Novavax and BioNTech Edge Higher247wallst.com
Oct-26-26
Oct-26-2606:46PM
Novavax (NVAX) Stock Falls Amid Market Uptick: What Investors Need to Knowzacks.com
Oct-24-26
Oct-24-2603:09AM
What Novavax Doubters OverlookedYahoo
Oct-21-26
Oct-21-2610:00AM
Investors Heavily Search Novavax, Inc. (NVAX): Here is What You Need to Knowzacks.com
Oct-19-26
Oct-19-2606:46PM
Novavax (NVAX) Stock Declines While Market Improves: Some Information for Investorszacks.com
04:38AM
Novavax's Second-Largest Shareholder Sells $32.6 Million in Stock, Ends Activist PushBenzinga
Oct-18-26
Oct-18-2602:21AM
Novavax (NASDAQ:NVAX) Shares Down 9.1% – Here’s What Happeneddefenseworld.net
Oct-16-26
Oct-16-2605:24PM
Novavax shareholder Shah Capital to step back from activist rolereuters.com
03:36PM
Moderna and Novavax Stocks Slump as Biotech's Rally Takes a Breatherbarrons.com
12:44PM
Novavax Plunges 12% as Selloff Hits Vaccine Makers; Moderna Tumbles 10%, Pfizer Holds Steady247wallst.com
Oct-13-26
Oct-13-2606:45PM
Novavax (NVAX) Increases Despite Market Slip: Here's What You Need to Knowzacks.com
Oct-12-26
Oct-12-2610:23PM
Moderna Stock Soared 14% as NIH Plans COVID-Style Push for Cancer VaccinesYahoo
Company

Novavax, Inc. is a biotechnology firm dedicated to discovering, developing, and commercializing vaccines aimed at preventing serious infectious diseases and addressing critical health needs. The company's diverse pipeline includes NVX-CoV2373, a coronavirus vaccine candidate currently undergoing two Phase III trials, one Phase IIb, and one Phase I/II trial. Also featured is NanoFlu, a nanoparticle-based seasonal quadrivalent influenza vaccine in Phase 3 clinical trials. Furthermore, Novavax is advancing ResVax, a respiratory syncytial virus (RSV) fusion (F) protein nanoparticle vaccine, which is in Phase II clinical trials for adults aged 60 and older, and in Phase I for pediatric use. The company holds a collaboration agreement with Takeda Pharmaceutical Company Limited for the development, manufacturing, and commercialization of its COVID-19 vaccine candidate, NVX-CoV2373. Established in 1987, Novavax, Inc. is headquartered in Gaithersburg, Maryland.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
FY 2025
12/31/2025
FY 2024
12/31/2024
FY 2023
12/31/2023
FY 2022
12/31/2022
FY 2021
12/31/2021
FY 2020
12/31/2020
FY 2019
12/31/2019
FY 2018
12/31/2018
FY 2017
12/31/2017
Total Revenue1,123682556——————
Cost of Goods Sold Incl. D&A71203344——————
Gross Profit1,052479213——————
Selling, General and Administrative Excl. Other150337469——————
Research and Development337391738——————
Other Operating Expense20-428——————
Operating Income563-249-567——————
Interest Expense232014——————
Unusual Expense
—————————
Non-Operating Income (Expense)-999238——————
Net Income Before Taxes442-177-543——————
Income Taxes2112——————
Consolidated Net Income440-187-545——————
Net Income From Continuing Operations440-187-545——————
Net Income440-187-545——————
EPS (Recurring)2.72-1.23-5.41——————
EPS (Basic, Before Extraordinaries)2.72-1.23-5.41——————
EPS (Diluted)2.54-1.23-5.41——————
EBITDA492-108-487——————
Other After Tax Adjustments
—————————
Stock Option Compensation Expense
—————————
Price To Earnings Ratio2.65————————
Price To Sales Ratio0.971.790.87——————
Gross Margin93.6870.2338.31——————
Operating Margin50.13-36.51-101.98——————
Net Margin39.18-27.42-98.02——————
Shares Outstanding162152101——————
Market Capitalization1,0891,222485——————
Operating Lease Expense
—————————
Unlock full historical data
See years of past statements with Premium.
Unlock with Premium
Insider Trading Volume
$13.81$11.66$9.52$7.37$5.23● Close Price0.00K0.00K0.00K0.00K0.00KUSD Trades VolumeNovDec2026FebMarAprMayJunJulAugSepOctNov
Insider Trading
InsiderRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Form 4
DOUGLAS RICHARDDirectorJun 20 '26Option Exercise0.0018,880073,220Jun 23
Rodgers Richard JDirectorJun 20 '26Option Exercise0.0018,880047,370Jun 23
MOTT DAVID MDirectorJun 20 '26Option Exercise0.0018,880079,770Jun 23
King Rachel K.DirectorJun 20 '26Option Exercise0.0018,880044,070Jun 23
MCGLYNN MARGARET GDirectorJun 20 '26Option Exercise0.0018,880044,468Jun 23
Alton Gregg HDirectorJun 20 '26Option Exercise0.0018,880047,685Jun 23
Newton Charles W.DirectorApr 25 '26Option Exercise0.009,52009,520Apr 28
Shiver John W.DirectorMar 10 '26Option Exercise0.007,94707,947Mar 12
Kelly James PatrickEVP, CFO and TreasurerMar 07 '26Option Exercise0.0012,2230136,503Mar 09
Casey Mark JEVP, Chief Legal OfficerMar 03 '26Option Exercise0.0041,5000101,445Mar 05
Kelly James PatrickEVP, CFO and TreasurerMar 03 '26Option Exercise0.0043,1670145,130Mar 05
Jacobs John CPresident and CEOMar 03 '26Option Exercise0.00150,1670264,130Mar 05
O'Hara ElaineEVP, Chief Strategy OfficerMar 03 '26Option Exercise0.0056,3340157,071Mar 05
Draghia-Akli RuxandraEVP, Research & DevelopmentMar 03 '26Option Exercise0.0026,667034,876Mar 05
O'Hara ElaineEVP, Chief Strategy OfficerMar 01 '26Option Exercise0.0059,6000111,706Mar 03
open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.